Salix Pharmaceuticals, Ltd. Release: FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date For RELISTOR® Subcutaneous Injection Snda For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-Cancer Pain

RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today announced that the Food and Drug Administration (FDA or Agency) has informed Salix that the supplemental New Drug Application (sNDA) for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29, 2014.

Help employers find you! Check out all the jobs and post your resume.